Glenmark Pharmaceuticals Board Meeting on July 31 to Approve Unaudited Financial Results

Glenmark Pharmaceuticals Ltd has announced that its Board of Directors will convene on July 31, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The results will be both standalone and consolidated. The company will submit the financial results to the stock exchanges and host them on its website on the same day. Additionally, the trading window for designated persons will remain closed from July 1, 2026, until 48 hours after the declaration of results, reopening on August 3, 2026.